Table 4 Expected cost-effectiveness of vaccination strategies
From: Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Strategy | Expected net costs per 100,000 people in 2020 USD | Expected total DALYs per 100,000 people | Expected incremental costs per 100,000 people versus next best non-dominated alternative | Expected DALYs averted per 100,000 people versus next best non-dominated alternative | ICER versus next best non-dominated alternative ($ per DALY averted) |
|---|---|---|---|---|---|
Scenario 1: When an outbreak occurs over the 10-year time horizon | |||||
Reactive vaccination (routine + campaign) | $111,213 | 383 | – | – | – |
No vaccination (base case) | $128,360 | 689 | – | – | Dominated |
Preventative vaccination (routine + campaign) | $131,749 | 316 | $20,536 | 67 | 307 |
Preventative vaccination (routine only) | $154,148 | 472 | – | – | Dominated |
Scenario 2: When no outbreak occurs (pre-outbreak incidence) | |||||
No vaccination (base case) | $5893 | 35 | – | – | – |
Preventive vaccination (routine only) | $26,704 | 22 | – | – | Dominated |
Preventative vaccination (routine + campaign) | $27,109 | 11 | $21,216 | 24 | 902 |
Scenario 3: When an outbreak has already occurred (post-outbreak incidence) | |||||
No vaccination (base case) | $7242 | 577 | – | – | – |
Preventive vaccination (routine + campaign) | $49,406 | 295 | $42,164 | 282 | 150 |
Preventative vaccination (routine only) | $51,717 | 372 | – | – | Dominated |